A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

ClinicalTrials.gov ID: NCT04691154

Public ClinicalTrials.gov record NCT04691154. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease

Study identification

NCT ID: NCT04691154
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Liquidia Technologies, Inc.; Industry
Enrollment: 28 participants

Conditions and interventions

Conditions

Interventions

L606 inhalation suspension Combination Product

Combination Product

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2021
Primary completion: Mar 19, 2025
Completion: Mar 30, 2031
Last update posted: Mar 31, 2026

2021 – 2031

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Arizona Pulmonary Specialists	Scottsdale	Arizona	85258	—
VA Greater Los Angeles Healthcare	Los Angeles	California	90073	—
Mayo Clinic Jacksonville	Jacksonville	Florida	32224	—
University of South Florida	Tampa	Florida	33606	—
Icahn School of Medicine at Mount Sinai	New York	New York	10029-6504	—
University of Cincinnati Medical Center	Cincinnati	Ohio	45267	—
Summit Health Eastside Clinic	Bend	Oregon	97701	—
Baylor Scott and White Research Institute	Temple	Texas	76508	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04691154, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 31, 2026 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04691154 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →